May 17, 2018
Celularity and New York Medical College Partner on a Breakthrough Study to Treat RDEB with Human Placental Derived Stem Cells
May 17, 2018
BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation
Feb 23, 2018
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease
Jan 10, 2018
Heart Failure Drugs Market - 10.46% CAGR to 2022 | ReportsnReports
Jan 09, 2018
Global Transplantation Therapeutics Market 2017 - Strong Unmet need for Prevention of Chronic Rejection
Jan 04, 2018
Cellect Announces Breakthrough Clinical Results
Dec 09, 2017
Immunotherapy Drug for Rheumatoid Arthritis Nearly Eliminates Severe Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant
Oct 31, 2017
Research Suggests New Way to Treat Inflammatory Gut Disease and Prevent Rejection of Bone Marrow Transplants
Oct 30, 2017
Janssen Inc. Announces IMBRUVICA® (ibrutinib) as the First Approved Treatment for Chronic Graft-Versus-Host Disease (cGVHD) Granted by Health Canada Priority Review
Oct 26, 2017
Omeros Reports Additional and Consistently Positive Data for OMS721 in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Oct 24, 2017
Neovii Announces Publication in Journal of Clinical Oncology Demonstrating Grafalon® Reduces Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplantation
Sep 19, 2017
Enlivex Therapeutics Announces Closing of USD 8 Million Series B Round Led by KOREA INVESTMENT PARTNERS (KIP) and HADASIT BIO HOLDINGINGS LTD. (HBL)
Sep 11, 2017
SpecificiT Raises Seed Financing
Sep 05, 2017
FDA Grants Orphan Drug Status to Cellect's ApoGraft(TM) for Acute GvHD and Chronic GvHD
Sep 04, 2017
Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021 with Bristol-Myers Squibb, Novartis, Pfizer & F. Hoffmann-La Roche Dominating
Aug 31, 2017
PMD Healthcare Supports Bone Marrow Transplant Study
Aug 09, 2017
Ocugen Receives FDA Orphan Drug Designation for OCU300 (brimonidine tartrate) for the Treatment of Ocular Graft Versus Host Disease
Aug 02, 2017
FDA approves treatment for chronic graft versus host disease
Aug 02, 2017
U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only Approved Treatment for Adult Patients with Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy
Jun 27, 2017
PMD Healthcare Supports Bone Marrow Transplant Study